But the investors at Arch Venture Partners are instead driven by frustration. Cofounder Robert Nelsen told reporters he was upset when hearing about shortages of COVID-19 treatments, surgical ...

The company is developing a care program focused on… Read More ARCH Venture Partners has closed a $2.975 billion fund targeted for early-stage biotech companies. The firm’s 12th venture fund ...

Weight-loss drug developer Metsera, backed by ARCH Venture Partners, revealed a wider loss in its paperwork for a U.S. initial public offering on Friday. The terms of the IPO were not disclosed in the ...

BioSpace recaps 2024’s top venture capital rounds in biopharma, from Xaira Therapeutics’ blockbuster $1B raise to ...

The initial funding was led by Arch Venture Partners, F-Prime Capital and Mubadala Capital with participation from other unnamed investors, according to a Jan. 8 release. Tenvie did not specify ...

Be Biopharma has secured $92m in a Series C financing round to advance its clinical programmes for haemophilia B and ...

In a bumper week for new biotech financings, debutante Kardigan ruled the roost with a $300 million first round that will ...

Almost five years after leaving Spark Therapeutics, Dr. Katherine High is back at the helm of a gene therapy company with ...

RhyGaze secured $86 million in a Series A financing round, which will be used to further the development of the company’s ...

Metsera has filed for an initial public offering. The clinical-stage biopharmaceutical company submitted a registration statement to regulators on Friday, saying it intends to list under the ticker ...

Metsera, founded in 2022 by venture capital firm ARCH Venture and investment firm Population Health Partners, revealed a net loss of $156.26 million in the first nine months of 2024, compared to a ...